JP2013545448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545448A5 JP2013545448A5 JP2013535100A JP2013535100A JP2013545448A5 JP 2013545448 A5 JP2013545448 A5 JP 2013545448A5 JP 2013535100 A JP2013535100 A JP 2013535100A JP 2013535100 A JP2013535100 A JP 2013535100A JP 2013545448 A5 JP2013545448 A5 JP 2013545448A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide antigen
- antigen
- polypeptide
- composition
- chlamydia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 792
- 102000036639 antigens Human genes 0.000 claims description 792
- 108091007433 antigens Proteins 0.000 claims description 792
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 652
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 651
- 229920001184 polypeptide Polymers 0.000 claims description 650
- 241000606161 Chlamydia Species 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 103
- 239000002671 adjuvant Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 5
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40516210P | 2010-10-20 | 2010-10-20 | |
| US61/405,162 | 2010-10-20 | ||
| PCT/US2011/057143 WO2012054755A1 (en) | 2010-10-20 | 2011-10-20 | Chlamydia antigens and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032672A Division JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013545448A JP2013545448A (ja) | 2013-12-26 |
| JP2013545448A5 true JP2013545448A5 (enExample) | 2014-12-04 |
Family
ID=45975625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535100A Pending JP2013545448A (ja) | 2010-10-20 | 2011-10-20 | クラミジア抗原及びその使用 |
| JP2016032672A Pending JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032672A Pending JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120135025A1 (enExample) |
| EP (1) | EP2629793A4 (enExample) |
| JP (2) | JP2013545448A (enExample) |
| AU (2) | AU2011316924A1 (enExample) |
| CA (1) | CA2849391A1 (enExample) |
| WO (1) | WO2012054755A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2432504B1 (en) | 2009-05-22 | 2019-05-01 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| US20130039947A1 (en) | 2010-03-12 | 2013-02-14 | Children's Medical Center Corporation | Novel immunogens and methods for discovery and screening thereof |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| AU2012340712B2 (en) * | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| AU2014214844B2 (en) | 2013-02-07 | 2017-12-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| US10350288B2 (en) | 2016-09-28 | 2019-07-16 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| JP6741919B2 (ja) | 2016-10-14 | 2020-08-19 | パナソニックＩｐマネジメント株式会社 | プロジェクションシステム、プロジェクション方法、飛行体システム及び飛行体 |
| US11013793B2 (en) | 2018-09-12 | 2021-05-25 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
| CA3231684A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
| JP2002529069A (ja) * | 1998-11-12 | 2002-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クラミジア・ニューモニエのゲノム配列 |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20050106162A1 (en) * | 2001-12-12 | 2005-05-19 | Guido Grandi | Immunisation against chlamydia trachomatis |
| US20040208890A1 (en) * | 2003-02-24 | 2004-10-21 | Institut Pasteur | Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof |
| MXPA05013260A (es) * | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
| EP2269636A3 (en) * | 2004-10-25 | 2011-04-06 | Statens Serum Institut | Chlamydia trachomatis antigens for vaccine and diagnostic use |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| EP1976557A2 (en) * | 2005-12-22 | 2008-10-08 | Novartis Vaccines and Diagnostics S.r.l. | Chlamydial antigens |
| JP2012505212A (ja) * | 2008-10-09 | 2012-03-01 | ボード・オヴ・リージェンツ，ユニヴァーシティ・オヴ・テキサス・システム | クラミジア感染および疾患の診断および治療のためのクラミジア抗原に関する方法および組成物 |
| EP2379106A4 (en) * | 2008-12-17 | 2012-06-13 | Genocea Biosciences Inc | ANTIGENS OF CHLAMYDIAS AND USES THEREOF |
| RU2011140508A (ru) * | 2009-03-06 | 2013-04-20 | Новартис Аг | Антигены хламидии |
-
2011
- 2011-10-20 JP JP2013535100A patent/JP2013545448A/ja active Pending
- 2011-10-20 US US13/277,996 patent/US20120135025A1/en not_active Abandoned
- 2011-10-20 EP EP11835162.6A patent/EP2629793A4/en not_active Withdrawn
- 2011-10-20 AU AU2011316924A patent/AU2011316924A1/en not_active Abandoned
- 2011-10-20 CA CA2849391A patent/CA2849391A1/en not_active Abandoned
- 2011-10-20 WO PCT/US2011/057143 patent/WO2012054755A1/en not_active Ceased
-
2016
- 2016-02-24 JP JP2016032672A patent/JP2016106117A/ja active Pending
- 2016-03-24 US US15/080,324 patent/US20170043005A1/en not_active Abandoned
- 2016-04-21 AU AU2016202528A patent/AU2016202528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545448A5 (enExample) | ||
| Lin et al. | Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| Bramwell et al. | The rational design of vaccines | |
| Dziadek et al. | Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice | |
| JP2012512257A5 (enExample) | ||
| JP2016106117A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| Li et al. | Co-stimulation with TLR7 agonist imiquimod and inactivated influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production | |
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| JP2012501959A5 (enExample) | ||
| JP2025085695A (ja) | 既存の微生物免疫を利用した癌処置 | |
| EP2909238A1 (en) | Improved human herpesvirus immunotherapy | |
| JP2015529677A5 (enExample) | ||
| TWI507413B (zh) | 脂質化多抗原表位疫苗 | |
| Zhao et al. | Enhanced immune response and protective efficacy of a Treponema pallidum Tp92 DNA vaccine vectored by chitosan nanoparticles and adjuvanted with IL-2 | |
| Alipour et al. | The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice | |
| Maraghi et al. | Evaluation of immunogenicity and protective effect of DNA vaccine encoding surface antigen1 (SAG1) of Toxoplasma gondii and TLR-5 ligand as a genetic adjuvant against acute toxoplasmosis in BALB/c mice | |
| Khateri et al. | Evaluation of autophagy induction on HEV 239 vaccine immune response in a mouse model | |
| Maspi et al. | DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice | |
| Ge et al. | Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70 | |
| Adam et al. | A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity | |
| JP2023526766A (ja) | ヒトサイトメガロウイルスポリエピトープワクチン組成物 | |
| Zhan et al. | Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen | |
| Ming et al. | Drilling dendritic cell activation: Engineering interfacial mechano-biochemical cues for enhanced immunotherapy |